During Premier Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Article
| April 26, 2021
5 Key Takeaways: Insights On Alternative Designs To The Traditional 3+3 Design In Phase 1 Dose Escalation Studies
By Abie Ekangaki and Andreas Schreiner
Traditionally, Phase 1 trials commonly utilize 3+3 designs to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Studies have shown, however, that two out of three trials employing a 3+3 design failed in identifying the MTD, and better approaches are needed.1
During Premier Research’s recent webinar Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies, Abie Ekangaki, Vice President, Statistical Consulting, and Andreas Schreiner, Vice President, Medical Affairs, Neuroscience & Analgesia, discuss alternative dose-escalation paradigms introduced into the clinical trial landscape for Phase 1 trials. In this blog post, we share five of their key insights on alternative dose escalation strategies for ....

Andreas Schreiner , During Premier Research , Abie Ekangaki , Premier Research , Alternative Designs , Escalation Studies , Vice President , Statistical Consulting , Medical Affairs , ஆண்ட்ரியாஸ் ஸ்ச்சிரேனேற் , ப்ரிமியர் ஆராய்ச்சி , மாற்று வடிவமைப்புகள் , துணை ப்ரெஸிடெஂட் , புள்ளிவிவர ஆலோசனை , மருத்துவ வாழ்க்கைத்தொழில்கள் ,